Chengliang Yin1,2,3, Junyan Zhang1,3, Wei Guan4, Liping Dou4, Yuchen Liu4, Ming Shen5, Xiaodong Jia6, Lu Xu5, Rilige Wu1,3, Yan Li4,7. 1. Medical Big Data Research Center, Medical Innovation Research Division of Chinese People's Liberation Army General Hospital, Beijing, China. 2. Faculty of Medicine, Macau University of Science and Technology, Macau, China. 3. National Engineering Laboratory for Medical Big Data Application Technology, Chinese People's Liberation Army General Hospital, Beijing, China. 4. Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, China. 5. Research Center for Translational Medicine Laboratory, Medical Innovation Research Division of Chinese People's Liberation Army General Hospital, Beijing, China. 6. Hepatobiliary Surgery Center, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China. 7. Department of Hematology, Peking University, Third Hospital, Beijing, China.
Abstract
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease of the hematopoietic system, for which identification of novel molecular markers is potentially important for clinical prognosis and is an urgent need for treatment optimization. METHODS: We selected C-type lectin domain family 11, member A (CLEC11A) for study via several public databases, comparing expression among a variety of tumors and normal samples as well as different organs and tissues. To investigated the relationship between CLEC11A expression and clinical characteristics, we derived an AML cohort from The Cancer Genome Atlas (TCGA); we also investigated the Bloodspot and HemaExplorer databases. The Kaplan-Meier method and log-rank test were used to evaluate the associations between CLEC11A mRNA expression, as well as DNA methylation, and overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS). DNA methylation levels of CLEC11A from our own 28 de novo AML patients were assessed and related to chemotherapeutic outcomes. Bioinformatics analysis of CLEC11A was carried out using public databases. RESULTS: Multiple public databases revealed that CLEC11A expression was higher in leukemia. The TCGA data revealed that high CLEC11A expression was linked with favorable prognosis (OS p-value = 2e-04; EFS p-value = 6e-04), which was validated in GSE6891 (OS p-value = 0; EFS p-value = 0; RFS p-value = 2e-03). Methylation of CLEC11A was negatively associated with CLEC11A expression, and high CLEC11A methylation level group was linked to poorer prognosis (OS p-value = 1e-02; EFS p-value = 2e-02). Meanwhile, CLEC11A hypermethylation was associated with poor induction remission rate and dismal survival. Bioinformatic analysis also showed that CLEC11A was an up-regulated gene in leukemogenesis. CONCLUSION: CLEC11A may be used as a prognostic biomarker, and could do benefit for AML patients by providing precise treatment indications, and its unique gene pattern should aid in further understanding the heterogeneous AML mechanisms.
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease of the hematopoietic system, for which identification of novel molecular markers is potentially important for clinical prognosis and is an urgent need for treatment optimization. METHODS: We selected C-type lectin domain family 11, member A (CLEC11A) for study via several public databases, comparing expression among a variety of tumors and normal samples as well as different organs and tissues. To investigated the relationship between CLEC11A expression and clinical characteristics, we derived an AML cohort from The Cancer Genome Atlas (TCGA); we also investigated the Bloodspot and HemaExplorer databases. The Kaplan-Meier method and log-rank test were used to evaluate the associations between CLEC11A mRNA expression, as well as DNA methylation, and overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS). DNA methylation levels of CLEC11A from our own 28 de novo AML patients were assessed and related to chemotherapeutic outcomes. Bioinformatics analysis of CLEC11A was carried out using public databases. RESULTS: Multiple public databases revealed that CLEC11A expression was higher in leukemia. The TCGA data revealed that high CLEC11A expression was linked with favorable prognosis (OS p-value = 2e-04; EFS p-value = 6e-04), which was validated in GSE6891 (OS p-value = 0; EFS p-value = 0; RFS p-value = 2e-03). Methylation of CLEC11A was negatively associated with CLEC11A expression, and high CLEC11A methylation level group was linked to poorer prognosis (OS p-value = 1e-02; EFS p-value = 2e-02). Meanwhile, CLEC11A hypermethylation was associated with poor induction remission rate and dismal survival. Bioinformatic analysis also showed that CLEC11A was an up-regulated gene in leukemogenesis. CONCLUSION: CLEC11A may be used as a prognostic biomarker, and could do benefit for AML patients by providing precise treatment indications, and its unique gene pattern should aid in further understanding the heterogeneous AML mechanisms.
Authors: Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk Journal: N Engl J Med Date: 2016-06-09 Impact factor: 91.245
Authors: Deepa Bhojwani; Huining Kang; Naomi P Moskowitz; Dong-Joon Min; Hokyung Lee; Jeffrey W Potter; George Davidson; Cheryl L Willman; Michael J Borowitz; Ilana Belitskaya-Levy; Stephen P Hunger; Elizabeth A Raetz; William L Carroll Journal: Blood Date: 2006-07-15 Impact factor: 22.113
Authors: Asim Khwaja; Magnus Bjorkholm; Rosemary E Gale; Ross L Levine; Craig T Jordan; Gerhard Ehninger; Clara D Bloomfield; Eli Estey; Alan Burnett; Jan J Cornelissen; David A Scheinberg; Didier Bouscary; David C Linch Journal: Nat Rev Dis Primers Date: 2016-03-10 Impact factor: 52.329
Authors: Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur Journal: Cancer Date: 2010-11-29 Impact factor: 6.860
Authors: F Iffet Sahin; E Kizilkilic; T Bulakbasi; Z Yilmaz; C Boga; O Ozalp; S Karakus; H Ozdogu Journal: Clin Exp Med Date: 2007-10-03 Impact factor: 3.984
Authors: Frederik Otzen Bagger; Nicolas Rapin; Kim Theilgaard-Mönch; Bogumil Kaczkowski; Lina A Thoren; Johan Jendholm; Ole Winther; Bo T Porse Journal: Nucleic Acids Res Date: 2012-11-09 Impact factor: 16.971